FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
03/21/2023
Back to search
Official data from USPTO
B
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
27
Latest update
03/21/2023
Trademark type
Combined
Nice classes
5
Filing date
05/24/2021
Registration date
11/01/2022
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
11/01/2022
Last transaction
11/01/2022
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
3
Owner type
99
Owner location
CN
Examiner
BLOHM, LINDA
Law office
M10
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of the left-slanting capital letter "B" in blue and the parallelogram on the upper left corner of the "B" in green. The white background is not claimed as a feature of the mark.
Holders and representatives
Holders
Chengdu Brilliant Pharmaceutical Co., Ltd.
Representatives
Paulo A. de Almeida Patel & Almeida, P.C.
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Cultures of microorganisms for medical or veterinary use; medical dressings; pharmaceutical preparations for human use for the treatment of viralmetabolicendocrinemusculoskeletalcardiovascularcardiopulmonarygenitourinarysexual dysfunctiononcologicalhepatologicalophthalmicrespiratoryneurologicalgastrointestinalhormonaldermatologicalpsychiatric and immune system related diseases and disorders; pharmaceutical preparations for human use for the prevention and treatment of ocular disorders or diseasesbacteria-based diseases or disordersautoimmune diseases or disorderskidney diseases or disordersdiabetes; pharmaceutical preparations for human use for the treatment of infectious diseasesblood disorderspaininflammationsepsisalopeciaobesity and cognitive disorders; pharmaceutical preparations for human useanti-infectives; antifungal pharmaceutical preparations for human use; Chinese traditional medicinal herbs for human use; pharmaceutical preparations for human use for antitussive-cold; pharmaceutical preparations for human use for the prevention and treatment of cancer; pharmaceutical preparations for human use for the treatment of psychiatric diseases and disorders; pharmaceutical preparations for human use for the treatment of heart rhythm disorders; medicated throat sprays for human use; diuretic pharmaceutical preparations for human use; pharmaceutical preparations for human use for the treatment of musculo-skeletal disorders; pharmaceutical preparations for human use for the treatment of hyperlipidemia; antitussives for human use; otorhinolaryngological pharmaceutical preparations for human use; anaesthetics for human use; pharmaceutical preparations for humanantidepressants; pharmaceutical preparations for human use for the treatment of eye diseases and conditions; headache treatment pharmaceutical preparations for human use; nasal spray preparations for human use; medicines for human use for the treatment of gastrointestinal diseases; medicinal preparations for the mouth and as sprays for human use; thyroid and para-thyroid hormone pharmaceutical preparations for human use; sulfonamide pharmaceutical preparations for human use; pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension for human use; pharmaceutical preparations acting on the central nervous system for human use; pharmaceutical preparations for human use for the treatment of erectile dysfunction; pharmaceutical solutions used in dialysis for human use; pharmaceutical preparations for human use for the treatment of bone diseases; antipyretic analgesics for human use; antiallergic medicines for human use; anti-diabetic pharmaceutical preparations for human use; hypnotic sedatives for human use; cardiovascular pharmaceutical preparations for medical purposes for human use; hemostatics for medical purposes for human use; antihemorrhoidal pharmaceutical preparations for human use; anti-epileptic pharmaceutical preparations for human use; cerebral hemorrhage prophylactic pharmaceutical preparations for human use; pharmaceutical preparations for human use for the treatment of immune system related diseases and disorders; pharmaceutical preparations for human use for treating hypertension; athlete's foot pharmaceutical preparations for human use; pharmaceutical preparations for human use for treating asthma; pharmaceutical preparations for human use for the treatment of hormonal disorders; medicated mouth treatment pharmaceutical preparations for human use; motion sickness medicines for human use; diarrhea medication for human use; pesticides; medicines for veterinary purposespain relief medication; veterinary vaccines; anti-infectives products for veterinary use; bacteriological medicinal preparations for veterinary purposes; medicines for veterinary purposesfor treatment of intestinal bacteria; medicines for veterinary purposes for the treatment of animals' skin diseases; medicines for veterinary purposes for the treatment of wounds; albumin dietary supplements for medical purposes; depuratives for the body; oxygen for medical purposes; nitrous oxide for medical use; radioactive substances for medical purposes
Publications
History of USPTO decisions and trademark events.
27 publications found
FICS
FINAL DISPOSITION NOTICE SENT TO IB
02/28/2023
FIMP
FINAL DISPOSITION PROCESSED
02/27/2023
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
02/01/2023
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
11/01/2022
R.PR
REGISTERED-PRINCIPAL REGISTER
11/01/2022
DOCK
ASSIGNED TO EXAMINER
10/17/2022
GPNX
NOTIFICATION PROCESSED BY IB
08/17/2022
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
08/16/2022
PUBO
PUBLISHED FOR OPPOSITION
08/16/2022
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
07/27/2022
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
07/27/2022
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
07/27/2022
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
07/11/2022
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
07/08/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
07/07/2022
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
07/07/2022
RFNT
REFUSAL PROCESSED BY IB
04/04/2022
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
03/14/2022
RFRR
REFUSAL PROCESSED BY MPU
03/14/2022
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
02/12/2022
CNRT
NON-FINAL ACTION WRITTEN
02/11/2022
DOCK
ASSIGNED TO EXAMINER
02/04/2022
MAFR
APPLICATION FILING RECEIPT MAILED
11/12/2021
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
11/08/2021
LIMI
LIMITATION FROM ORIGINAL APPLICATION ENTERED
11/05/2021
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
10/29/2021
Continuous trademark protection
Get notified about every new filing that threatens B or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.